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ABSTRACT
Chitosan is known for its lipid-lowering effect. To investigate the comparative effects of low (LCS) and high molecular weight
chitosan (HCS) on plasma glucose, cholesterol and adipocytokines, male Sprague-Dawley rats were divided into four groups: normal
control, diabetic, and diabetic fed the HCS or LCS diet for seven weeks. Diabetes was induced by subcutaneous injection of nicotinamide
and streptozotocin. Results showed that diabetic rats fed the HCS diet had reduced liver weight and perirenal adipose weight, compared
to those that were fed the control diet. Higher fecal triglyceride and cholesterol excretion and lower hepatic cholesterol and triglyceride
contents were found in diabetic rats fed with both chitosan diets. These observations were more significant in the HCS group than in the
LCS group. HCS, but not LCS diet, significantly reduced plasma fructosamine, leptin, total cholesterol and lowered the insulin resistance
index (homeostasis model assessment; HOMA) in diabetic rats. A lower intestinal dissaccharidase activity including sucrase and lactase
was found in diabetic rats fed the HCS diet. Moreover, plasma tumor necrosis factor-alpha and plasminogen activator inhibitor-1 concentrations were significantly reduced by both chitosan supplementations. The results suggested that HCS feeding may reduce insulin resistance
by the suppression of lipid accumulation in liver and adipose tissue and amelioration of chronic inflammation in diabetic rats. HCS may
improve glucose and lipid metabolism more significantly than LCS in diabetic rats.
Key words: chitosan, molecular weight, diabetes, insulin resistance, adipocytokines

INTRODUCTION
Diabetes mellitus (DM) is a chronic metabolic disease.
Statistical analysis has shown that more than 90% of diabetic
patients suffer from type 2 DM. Type 2 DM is mostly caused
by obesity and insulin resistance, and increases the risk of
cardiovascular diseases(1,2). Moreover, obesity refers to an
excessive amount of adipose tissue, which is an important
endocrine organ that secretes adipocytokines such as leptin
that may influence energy metabolism and affect insulin
actions(3). In addition, some cytokines such as tumor necrosis
factor-alpha (TNF-α) and plasminogen activator inhibitor-1
(PAI-1) can also be secreted by adipose tissue(1,4). PAI-1 is a
key element in the inhibition of fibrinolysis and plays a role
in the development of atherosclerosis in diabetic patients(5). It
can be stimulated with various inflammatory cytokines, such
as TNF-α. Indeed, increased TNF-α and PAI-1 have been
shown to enhance insulin resistance and atherosclerosis in
* Author for correspondence. Tel: +886-2-24622192 ext. 5117/5118;
Fax: +886-2-24634203; E-mail: a0071@mail.ntou.edu.tw

diabetic subjects(5,6).
Many studies reported that dietary fibers are suggested
to have beneficial effects on the plasma lipids of patients
with diabetes and atherosclerosis. Chitosan is a dietary
fiber produced by the deacetylation of chitin. Its chemical
structure is similar to cellulose, linked by β (1→4) glycosidic linkage, and is not digested by mammalian digestive
enzymes(7). Chitosan is generally known for its plasma
cholesterol-lowering effect due to an increase of fecal fat
excretion(8,9). Many investigators demonstrated that chitosan
may have beneficial effects on the reduction of adipose tissue
in rodents(10,11). Recent studies have also demonstrated that
chitosan decreased plasma glucose concentrations in type 1
diabetic rats and the action mechanism probably involved
a decrease in liver gluconeogenesis, an increase in skeletal
muscle glucose uptake and use(12) and lower intestinal disaccharidase activities(10). A few studies have shown that chitosans with different molecular weights (MW) have different
hypocholesterolemic and hypoglycemic effects. Yao et
al.(10) reported that high molecular weight (MW) chitosan
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(average MW: 1.0 × 106 dalton) had greater ability to lower
plasma glucose and cholesterol concentrations than low MW
chitosan (average MW: 1.4 × 104 dalton) in STZ-induced
diabetic rats. LeHoux and Grondin(13), however, reported
that a chitosan sample with average MW greater than 7.5 ×
105 dalton, had less hypocholesterolemic effect than that of
chitosan with low MW (average MW: 7 × 104 dalton). Other
studies show that low MW chitosan (average MW of about
2 × 104 dalton)(14,15) and chitosan oligosaccharides(16) can
also reduce plasma glucose level in diabetic animals. These
results indicate that the effects of chitosan with low or high
molecular weight on plasma glucose and cholesterol concentrations are still inconclusive.
Streptozotocin (STZ) is an antibiotic from Streptomyces
achromogenes. It can selectively damage the pancreatic β-cell
and develop hypoinsulinemia and high blood glucose similar
to type 1 DM animals(17). Pretreatment of nicotinamide can
scavenge free radicals and recruit the consumption of nicotinamide adenine dinucleotide (NAD+) in pancreatic β-cell
after STZ injection. Hence the injection of nicotinamide can
partially protect the pancreatic β-cell after STZ injection and
then develop mild hyperglycemia(17). Chitosan has been shown
to reduce plasma cholesterol and adipose weight(11,18) and
improve glucose metabolism in type 1 diabetic rats(12). The
effect of chitosan on type 2 DM is less discussed. The present
study was to investigate the comparative effects of high MW
chitosan (average MW: 8.6 × 105 dalton) and low MW chitosan
(average MW: 1.8 × 104 dalton) on plasma glucose, lipids and
adipocytokines (e.g. adiponectin, TNF-α, leptin and PAI-1)
in a diabetic rat model induced by STZ and nicotinamide.

MATERIALS AND METHODS
I. High Molecular Weight Chitosan (HCS) and Cellulose
HCS from shrimp shell was generously supplied by
Taiwan Tanabe Seiyaku Co., Ltd (Taipei, Taiwan). Cellulose
was purchased from Sigma Chemical Co. (USA).
II. Preparation of Low Molecular Weight Chitosan (LCS)
LCS was prepared from HCS using the method of
Vårum et al.(19) with slight modification. HCS powder was
dissolved in 8 N HCl with stirring and hydrolyzed at 55°C
for 3 h. Subsequently, 8 N NaOH was used to stop the reaction in an ice bath and a pH of 9-10 was obtained. After the
precipitation of LCS, the supernatant was removed and the
LCS was washed with distilled water (pH 7). The fluid was
then centrifuged at 12,000 ×g for 30 min (4°C). The LCS
powder was obtained by freeze-drying the precipitate.
III. Determination of Average Molecular Weight (MW),
Degree of Deacetylation (DD) and Viscosity of Chitosan
Samples
The average MW was determined by the Mark-Houwink

equation(20). Five concentrations of chitosan solution (0.01,
0.025, 0.05, 0.075 and 0.1%) were prepared. The intrinsic
viscosity (η) was measured in a 0.2 M CH3COOH/0.1 M
CH3COONa solution using Cannon Fenske, No. 100 capillary viscometer at 30°C(21). The viscosity MW (M) was
calculated by the Mark-Houwink equation(20): η = KMa
The constants, K and a, were dependent on DD, where
DD was expressed as the percentage: K = 1.64 × 10-30 ×
DD14; a = -1.02 × 10-2 × DD + 1.82
DD was assayed by Fourier transform infrared spectroscopy (FTIR)(22). Chitosan powder was mixed with KBr
(1 : 100) and pressed into a pellet. The absorbance values
of amide 1 (1655 cm-1) and the hydroxyl band (3450 cm-1)
were measured by a Bio-Rad FTS-155 infrared spectrophotometer. The percentage of the amine group’s acetylation in a
sample is given by (A1655/A3450) × 115. A1655 and A3450 are
the absorbance values at 1650 and 3450 cm-1, respectively.
IV. Animals and Treatment
Six-week-old male Sprague-Dawley rats were purchased
from BioLASCO Taiwan Co., Ltd. (Taiwan). The Rats were
fed a chow diet (Rodent Laboratory Chow, Ralston Purina, St.
Louis, MO, USA) for 3 weeks and diabetic rats were induced
by the intraperitoneal injection of nicotinamide (230 mg/
kg body weight in water) 15 min prior to the intraperitoneal
injection of STZ (60 mg/kg body weight in 0.05 M citrate
buffer; pH 4.5)(17). The non-diabetic group (cellulose control
group) also received nicotinamide prior to the injection of
citrate buffer alone. Seven days after the STZ+nicotinamide
injection, the diabetic rats were checked for plasma glucose
concentration after a 2-h oral glucose tolerance test (OGTT; 2
g glucose/kg body weight). Except for fasting glucose level,
the plasma glucose concentration was more than 200 mg/
dL within 2 h after glucose challenge to confirm the diabetic
status. The diabetic rats were then divided into three groups
with 7 to 9 rats in each group. One group was treated with a
5% cellulose control diet (the same diet as the control group),
while the other two groups were treated with 5% LCS and 5%
HCS diets, respectively. The rats were fed the experimental
diets for seven weeks. The physiochemical properties of
chitosan samples and composition of the experimental diet
given to test animals are shown in Table 1. The rats were
housed in individual stainless steel cages in a room kept at
23 ± 1°C and 60 ± 5% relative humidity with a 12-h light and
dark cycle. Food and drinking water were available ad libitum
and measured daily. Body weight was measured every week.
Feces and urine were collected during the final 3 days of the
experiment. The feces samples were then dried and weighed.
This study was approved by the Animal House Management
Committee of the National Taiwan Ocean University. The
animals were maintained in accordance with the guidelines
for the care and use of laboratory animals as issued by the
Animal Center of the National Science Council.
V. Collection of Plasma and Tissue Samples
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Table 1. Composition of experimental diets (%)
Dieta

Control/DM

LCS

HCS

Casein

20

20

20

Lard

8

8

8

Corn oil

2

2

2

b

1

1

1

b

5

5

5

Cholesterol

0.5

0.5

0.5

Choline chloride

0.2

0.2

0.2

Vitamin mixture
Mineral mixture

Cellulose

5

Low molecular weight chitosan (LCS)c

5

d

High molecular weight chitosan (HCS)
Corn starch

5
58.3

58.3

58.3

a

Control: Nondiabetic with cellulose diet; DM: Diabetic with cellulose diet; LCS: Diabetic with low molecule weight chitosan diet; HCS:
Diabetic with high molecule weight chitosan diet.
b
AIN 76 vitamin and mineral mixtures: procured from ICN Biochemicals (Costa Mesa, CA, USA)
c
The average MW and viscosity of chitosan were about 1.8 × 104 dalton and 27 cps, respectively. The degree of deacetylation was about 95%.
d
The average MW and viscosity of chitosan were about 8.6 × 105 dalton and 538 cps, respectively. The degree of deacetylation was about 93%.

At the end of the experiment, the rats were fasted overnight and then sacrificed by exsanguinations via the abdominal aorta while under diethyl ether anesthesia. Heparin was
used as the anticoagulant. Plasma was separated by centrifugation at 1,570 ×g for 20 min (4°C) from the blood. Liver and
adipose tissues (perirenal and epididymal) were excised from
each rat and weighed. All the tissue samples were immediately frozen and were stored at -80°C until further analysis.
VI. Determination of Plasma Glucose, Fructosamine, Insulin,
Adiponectin, Leptin, TNF-α, PAI-1 and Insulin Resistance
Measurement

concentration of HDL-C in plasma was determined after
plasma ultracentrifugation (194,000 ×g for 3 h at 10°C)
(24)
. The total cholesterol levels of the HDL fraction were
measured by applying the same method on the plasma. The
VLDL-C + LDL-C concentration was calculated as the difference between total cholesterol and HDL-C.
Hepatic lipids and fecal lipids were extracted by chloroform/methanol solution (2 : 1) according to the method of
Folch et al.(25). The extracts were dissolved in Triton X-100
by the method of Carlson and Goldfarb(26) and then the total
cholesterol and triglyceride concentrations in liver and feces
were assayed by commercial kits (Audit Diagnostics, Ireland).

Plasma concentrations of glucose (Kyokuto Pharmaceutical Industrial Co., Ltd., Japan) and fructosamine (Hospitex
Diagnostics, Italy) were assayed by commercial kits. Plasma
insulin concentration was determined by rat insulin ELISA
kit (Mercodia AB, Sweden). Plasma leptin concentration was
measured by rat leptin ELISA kit (Assay Designs, Inc., USA).
Plasma tumor necrosis factor-alpha (TNF-α) concentration
was determined by rat TNF-α ELISA kit (R&D systems, Inc.,
USA). Plasma adiponectin concentration was assayed by rat
adiponectin ELISA kit (Chemicon International, Inc., USA).
The homeostasis model assessment (HOMA) was expressed
as an index of insulin resistance(23). HOMA = fasting glucose
concentration (mmol/L) × fasting insulin concentration
(mU/L) / 22.5

VIII. Determination of Intestinal Disaccharidase Activity

VII. Determination of Plasma Total Cholesterol, Hepatic
Lipids and Fecal Lipids Concentrations

Results are given as the mean ± SD values. Statistical
differences among the groups were calculated using one-way
ANOVA (SAS Institute, Cary, NC, USA) and were considered to be significant at p < 0.05, as determined by Duncan’s
new multiple-range test.

Plasma total cholesterol concentration was determined
by a commercial kit (Audit Diagnostics, Ireland). The

The preparation of mucosa samples from small intestine was described previously(10). Mucosa from each rat
was homogenized in saline over ice and the homogenate
was then centrifuged at 1,570 ×g for 10 min. The resulting
supernatant was used to determine the specific activities of
sucrase, maltase and lactase, according to the amount of
glucose released from sucrose, maltose and lactose, respectively, as described by Dahlqvist(27). The glucose concentration was determined with a test kit purchased from Audit
Diagnostics Co. (Cork, Ireland).
IX. Statistical Analysis
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RESULTS

groups in diabetic rats. Moreover, it is noteworthy that the
plasma concentrations of TNF-α and PAI-1 were significantly decreased in diabetic rats receiving HCS and LCS
diets. Lower plasma leptin level was observed in diabetic rats
receiving HCS diet.
As shown in Table 4, diabetic rats fed with HCS diet
had lower plasma total cholesterol and LDL-C + VLDL-C
concentrations. LCS feeding also decreased plasma LDL-C +
VLDL-C concentration, but the hypocholesterolemic ability
was lower than that of HCS in diabetic rats. The hepatic
total cholesterol and triglyceride contents are also shown in
Table 4. Chitosan feeding significantly reduced the hepatic
contents of cholesterol and triglycerides in diabetic rats, and
HCS tended to lower hepatic cholesterol and triglyceride
contents more significantly than LCS. This result indicated
that HCS was more effective than LCS in reducing hepatic
lipids content. In addition, HCS feeding increased fecal dry
and wet weight (data not shown) and enhanced fecal cholesterol and triglyceride excretion in diabetic rats. In addition to
HCS, LCS also enhanced fecal cholesterol and triglyceride
excretion (Table 4).
Intestinal disaccharidase activities including sucrase,
maltase and lactase of diabetic rats are reported in Figure 1.
Diabetic rats fed the cellulose diet had no effect on intestinal
disaccharidase activities when compared with non-diabetic
rats fed the same diet. Lower lactase activity was found in

As shown in Table 2, there was no difference in body
weight among the animals in the four groups. Diabetic rats
fed the LCS or HCS diet had a statistically significant reduction in relative liver weight compared with diabetic rats fed
the cellulose diet after 7 weeks of feeding period. Moreover,
HCS significantly decreased the relative perirenal adipose
weight. There was no difference in food intake, volume of
drinking water and urine excretion among the four groups
(data not shown).
The effects of chitosan on plasma concentrations of
glucose, insulin, fructosamine, insulin and HOMA value in
diabetic rats are reported in Table 3. Diabetic rats fed the HCS
diet tended to have lower plasma concentrations of glucose
and insulin, but this difference was not significant. Lower
plasma fructosamine concentration and HOMA value were
observed in diabetic rats fed the HCS, but not rats fed the
LCS diet, indicating that insulin resistance was improved by
HCS. These results indicated that HCS was more effective
than LCS in reducing insulin resistance in diabetic rats.
Plasma adiponectin, leptin, TNF-α and PAI-1 in
diabetic rats are reported in Table 3. Diabetic rats had higher
plasma adiponectin levels than non-diabetic rats. There was,
however, no significant difference in the plasma adiponectin
concentrations of the cellulose and the chitosan-receiving

Table 2. Body weights, tissue weights and fecal weights of diabetic rats fed the chitosan diets for 7 weeks1
Control

DM

LCS

HCS

Initial body weight (g)

358.3 ± 22.9

348.0 ± 34.1

342.6 ± 24.5

345.1 ± 27.5

Final body weight (g)

511.2 ± 35.2

514.1 ± 29.8

486.2 ± 39.4

480.0 ± 42.9

*

Relative liver weight (g/100 g BW)

4.47 ± 0.65

4.52 ± 0.33

3.76 ± 0.33

3.02 ± 0.49*#

Relative perirenal adipose weight (g/100 g BW)

2.77 ± 0.89

2.93 ± 0.65

2.67 ± 0.58

2.14 ± 0.62*

Relative epididymal adipose weight (g/100 g BW)

1.92 ± 0.55

1.82 ± 0.21

1.72 ± 0.52

1.51 ± 0.48

Fecal wet weight (g/100 g BW)
2.91 ± 0.45
3.19 ± 0.46
3.30 ± 0.45
1
#
Data are mean ± SD values (n = 7-9). * p < 0.05, DM versus LCS or HCS; p < 0.05, LCS versus HCS.

4.25 ± 0.92*

Table 3. Plasma concentrations of glucose, fructosamine, insulin, TNF-α, leptin, PAI-1 and insulin resistance index (HOMA) of diabetic rats fed
the chitosan diets for 7 weeks1
Control

DM

LCS

HCS

Glucose (mg/dL)

174.5 ± 22.7**

190.6 ± 15.2

194.5 ± 16.8

179.5 ± 31.4

Fructosamine (mmol/L)

191.9 ± 35.8

206.1 ± 31.3

196.9 ± 26.9

165.5 ± 20.9*#

Insulin (mg/L)

1.03 ± 0.67

0.83 ± 0.35

0.79 ± 0.15

0.67 ± 0.21

HOMA2

9.06 ± 5.30

9.40 ± 1.97

7.35 ± 2.39

5.87 ± 2.37*

TNF-α (pg/mL)

55.3 ± 19.6**

99.4 ± 41.7

44.2 ± 1.23*

43.2 ± 1.78*

Leptin (ng/mL)

7.28 ± 0.93

7.51 ± 0.66

7.65 ± 0.49

6.44 ± 1.43*

PAI-1 (ng/mL)

2.15 ± 1.11**

4.12 ± 2.31

1.00 ± 0.53*

1.01 ± 0.33*

**

14.0 ± 2.8
15.4 ± 4.5
14.7 ± 4.9
9.87 ± 3.44
Adiponectin (mg/mL)
Data are mean ± SD values (n = 7-9).
2
Homeostasis model assessment (HOMA) equation for insulin resistance = (fasting plasma glucose concentration (mmol/L) × fasting plasma
insulin concentration (mU/L) / 22.5
** p < 0.05, Control versus DM; * p < 0.05, DM versus LCS or HCS; # p < 0.05, LCS versus HCS.
1
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Table 4. Plasma lipids, hepatic lipids and fecal lipids concentrations of diabetic rats fed the chitosan diets for 7 weeks1
Control

DM

LCS

HCS

72.4 ± 18.6

63.0 ± 10.1

50.9 ± 19.9*

Plasma
59.9 ± 17.9**

Total cholesterol (mg/dL)

**

HDL-C (mg/dL)

24.8 ± 7.8

28.5 ± 6.3

31.2 ± 5.2

34.3 ± 9.5

LDL-C + VLDL-C (mg/dL)

35.1 ± 14.3

43.9 ± 13.3

29.1 ± 5.9*

16.6 ± 11.2*#

Total cholesterol (mg/g liver)

61.5 ± 11.1

72.4 ± 14.8

30.4 ± 11.2*

16.4 ± 6.18*#

Triglyceride (mg/g liver)

71.6 ± 25.5

92.2 ± 16.5

51.2 ± 9.16*

44.3 ± 15.7*

Total cholesterol (mg/g dry feces)

16.0 ± 3.0

16.3 ± 2.1

26.9 ± 5.4*

25.5 ± 3.0*

Triglyceride (mg/g dry feces)

1.53 ± 0.56

1.25 ± 0.24

2.65 ± 0.42*

3.50 ± 0.84*#

Liver

Feces

1

Data are mean ± SD values (n = 7-9).
** p < 0.05, Control versus DM; * p < 0.05, DM versus LCS or HCS; # p < 0.05, LCS versus HCS.

mg glucose/min/mg protem

800

Maltase
Sucrase
Lactase

700
600
500
400
300
200
100
0

Control

DM

LCS

HCS

Figure 1. The changes of intestinal disaccharidases activities in diabetic
rats fed the chitosan diets for 7 weeks.1 Data are mean ± SD values
(n = 7-9). ** p < 0.05, Control versus DM; * p < 0.05, DM versus LCS
or HCS; #p < 0.05, LCS versus HCS.

diabetic rats fed with both chitosan diets. HCS, but not LCS,
reduced intestinal sucrase activity in diabetic rats.

DISCUSSION
According to our data, diabetic rats fed the HCS diet for
7 weeks exhibited significant reduction in lipid accumulation
in liver and adipose tissues and reduced plasma concentrations of adipocytokines including leptin, TNF-α and PAI-1.
Lower plasma fructosamine concentrations and insulin resistance (HOMA value) were observed in diabetic rats fed the
HCS diet. As fructosamine is a parameter that can present
short-term glucose metabolic status and reflect the average
plasma glucose concentration over the last 1-2 weeks, it is
suggested that HCS feeding may have beneficial effects on
glucose control and reduce insulin resistance in diabetic rats.
LCS, however, caused relatively less effect on these alternations in diabetic rats.
Chitosan has been shown to improve insulin sensitivity in obese subjects(28). Studies indicate that visceral

fat accumulation due to adipocyte hypertrophy induces the
secretion of leptin and TNF-α in adipocytes and thus increase
insulin resistance(29-31). The present study showed that lower
perirenal adipose tissue weight occurred in diabetic rats fed
HCS diets, but not LCS diet. HCS significantly decreased
plasma leptin and TNF-α levels, accompanied with a lower
adipose tissue weight in diabetic rats. Therefore, lower plasma
leptin and TNF-α level caused by HCS might be partly due
to lower adipose tissue weight in diabetic rats. In addition,
lower fructosamine and HOMA levels were observed in
animals fed the HCS diets. Thus, HCS may have the ability
to lower insulin resistance by reducing fat accumulation in
adipocytes and lowering plasma adipocytokines (e.g. leptin
and TNF-α) levels in diabetic rats. Furthermore, PAI-1 is a
key element in the inhibition of fibrinolysis and plays a role in
the development of atherosclerosis in diabetic patients(5,32).
The source of PAI-1 included endothelial cells, liver and
adipose tissue(33-35), which can be regulated by TNF-α(36).
In the present study, plasma TNF-α and PAI-1 levels were
increased in diabetic rats. However, this elevation could be
effectively reversed by both chitosan treatments. Therefore,
the reduction of plasma PAI-1 after chitosan feeding may
be related to the reduction of plasma TNF-α. Our results
indicated that chitosan feeding may reduce chronic inflammation in diabetic rats, at least in part, through the reduction of plasma TNF-α and PAI-1 levels. These observations
are consistent with the previous report that chitosan counteracts some inflammatory disorders that occur in high-fat
diet induced obese mice(12). Taken together, it is suggested
that chitosan may reduce chronic inflammation and thus
contribute to improving insulin resistance in diabetic rats.
HCS appeared to have greater effect on improving insulin
resistance than LCS in diabetic rats.
Liver can regulate the metabolic pathway of gluconeogenesis and glycolysis(37). Many studies demonstrated that
hepatic fat accumulation may reduce insulin sensitivity and
impaired glucose oxidation of liver cells(38,39). Our present
study revealed that hepatic cholesterol and triglyceride
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contents were significantly reduced by chitosan in diabetic
rats. The reduced liver weight may be attributed to the lower
hepatic lipid accumulation(10,13). HCS reduced hepatic lipids
more significantly than LCS. The reason for this observation
might be related to higher fecal lipids excretion caused by
HCS (Table 4). Therefore, the reduction of insulin resistance
by HCS treatment was not only due to a decrease in plasma
leptin and TNF-α levels but also lower hepatic lipid accumulation in diabetic rats.
Chitosan can be dissolved in acidic fluid and, therefore,
can become a highly viscous solution and act as viscous
dietary fiber in the stomach. Many viscous soluble dietary
fibers are capable of reducing the activity of intestinal disaccharidase and delaying gastric emptying. This will then slow
down the absorption of glucose and increase the insulin
sensitivity of the peripheral tissues and hence reduce plasma
glucose(40,41). In our present study, the viscosity of HCS (538
cps) was shown to be approximately 20 folds higher than LCS
(27 cps) in 0.1 M HCl solution. Hence, HCS may be more
capable than LCS in delaying gastric emptying and slowing
down the absorption of glucose. Furthermore, Yao et al.(10)
demonstrated that high MW chitosan (about 1.0 × 106 dalton)
had more ability in lowering intestinal disaccharidase activities than low MW chitosan (about 1.4 × 104 dalton) in type
1 STZ-induced diabetic rats. Our present study also found
that lower intestinal disaccharidase (sucrase and lactase)
activities were observed in diabetic rats after HCS treatment.
These results suggested that the glucose absorption in the
small intestines of diabetic rats might be slowed down after
feeding with diet containing HCS, which, in turn, may help
to control plasma glucose level after the meal. Additionally,
the present study demonstrated that only HCS had plasma
cholesterol-lowering effect in diabetic rats. LCS, however,
had no effect on plasma cholesterol level despite its ability
to reduce hepatic cholesterol content and increase fecal
cholesterol excretion. These results are similar to the results
of our previous study that the hypocholesterolemic ability of
chitosan in STZ-induced type 1 diabetic rats was dependent
on their molecular weight(10). HCS may entrap more lipids
and reduce fat digestion more significantly than LCS. Therefore, the different influences of high and low MW chitosans
on plasma cholesterol lowering effect appear to be related to
the differences in hepatic cholesterol contents, since high and
low MW chitosans have different inhibitory potentials on the
intestinal absorption of dietary cholesterol and triglycerides.
In conclusion, HCS feeding may improve insulin
resistance and chronic inflammation in STZ+nicotinamide
induced diabetic rats. The possible mechanisms may be
due to the decreased absorption of dietary lipids and slower
glucose absorption in the small intestines after the meal,
which may result in a decrease in hepatic lipids and adipose
tissue weight, and lowering of plasma levels of adipocytokine including leptin, TNF-α and PAI-1. HCS may improve
glucose and lipid metabolism more significantly than LCS in
diabetic rats.
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